Medigen Vaccine Biologics Cash Flow Reinvestment Rate

Latest as of December 2025: 3.00x

Medigen Vaccine Biologics cash flow reinvestment rate. Medigen Vaccine Biologics (6547) has a Cash Flow Reinvestment Rate of 3.00x as of December 2025, reinvesting NT$303.54 Million (capex NT$3.54 Million plus investments NT$300.00 Million) from operating cash flow of NT$101.08 Million. Explore Medigen Vaccine Biologics (6547) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

3.00x
(Capex + Investments) / Operating CF

Total Reinvested

NT$303.54 Million
Capex + Investments

Operating Cash Flow

NT$101.08 Million
TWD

Capital Expenditures

NT$3.54 Million
TWD

Cash Flow Reinvestment Rate of Medigen Vaccine Biologics (2015–2024)

Cash flow reinvestment rate of Medigen Vaccine Biologics from 2015 to 2024. Historical reinvestment intensity for Medigen Vaccine Biologics across 3 annual periods. Explore 6547 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Medigen Vaccine Biologics Cash Flow Reinvestment Rate by Year (2015–2024)

Medigen Vaccine Biologics cash flow reinvestment rate by year from 2015 to 2024. Year-by-year capital reinvestment analysis for Medigen Vaccine Biologics. For the full cash flow conversion analysis, see 6547 cash flow conversion.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2024 26.64x NT$1.09 Billion NT$40.75 Million NT$34.98 Million ▲ +1419.1%
2021 1.75x NT$1.02 Billion NT$579.89 Million NT$134.97 Million ▼ -17.1%
2015 2.11x NT$457.15 Million NT$216.26 Million NT$457.15 Million —
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow